Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：48
|
作者：
Assi, Tarek [1 ]
Kattan, Joseph [1 ]
Rassy, Elie [1 ,2 ]
Nassereddine, Hussein [1 ]
Farhat, Fadi [1 ]
Honore, Charles [2 ]
Le Cesne, Axel [2 ]
Adam, Julien [2 ]
Mir, Olivier [2 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon
[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷
关键词：
Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;
D O I：
10.1016/j.critrevonc.2020.103029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
    Shi, Chaoji
    Ju, Houyu
    Zhou, Rong
    Xu, Shengming
    Wu, Yunteng
    Gu, Ziyue
    Wang, Ying
    Chen, Wanling
    Huang, Xinyi
    Han, Yong
    Sun, Shuyang
    Li, Chuwen
    Wang, Min
    Zhou, Guoyu
    Zhang, Zhiyuan
    Li, Jiang
    Ren, Guoxin
    BMC MEDICINE, 2024, 22 (01):
  • [32] Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer
    Nina, Privsek
    Cvetka, Grasic Kuhar
    ONKOLOGIJA, 2021, 25 (02) : 48 - 53
  • [33] A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
    Zhang, Jialin
    Xu, Xinyu
    Zhou, Yeyue
    Su, Jingyang
    Wang, Jue
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [34] Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
    Yildirim, Hasan Cagri
    Mutlu, Emel
    Chalabiyev, Elvin
    Ozen, Mirac
    Keskinkilic, Merve
    On, Sercan
    Celebi, Abdussamet
    Dursun, Bengu
    Acar, Omer
    Kahraman, Seda
    Aykan, Musa Baris
    Kaman, Omur
    Dogan, Akif
    Erdogan, Atike Pinar
    Celayir, Ozde Melisa
    Gunenc, Damla
    Guven, Deniz Can
    Bayoglu, Ibrahim Vedat
    Yavuzsen, Tugba
    Hacibekiroglu, Ilhan
    Inanc, Mevlude
    Kilickap, Saadettin
    Yalcin, Suayib
    Aksoy, Sercan
    BREAST, 2022, 66 : 85 - 88
  • [35] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [36] Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
    Kwapisz, Dorota
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 41 - 54
  • [37] Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
    Dorota Kwapisz
    Breast Cancer Research and Treatment, 2017, 166 : 41 - 54
  • [38] Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
    Tamura, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 993 - 998
  • [39] Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer
    Hassan, Mohammed Al-Kassim
    Ates-Alagoz, Zeynep
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (04) : 412 - 428
  • [40] Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
    Kassem, Loay
    Shohdy, Kyrillus S.
    Lasheen, Shaimaa
    Abdel-Rahman, Omar
    Bachelot, Thomas
    BREAST CANCER, 2018, 25 (01) : 17 - 27
12345